» Articles » PMID: 2192793

Cytogenetics of Human Brain Tumors

Overview
Date 1990 Jul 15
PMID 2192793
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The most frequent cytogenetic alterations in primary brain tumors are losses of chromosomes or chromosomal regions and the presence of double minute chromosomes (dmins). The regions which are lost and the genes which are amplified are distinctive for individual tumor types. Most malignant gliomas contain gains of chromosome 7 and losses of chromosome 10; losses of chromosome 22, 9p, and the sex chromosomes occur in subgroups of cases. The gene most frequently amplified in tumors with dmins is the epidermal growth factor receptor gene. Medulloblastomas have losses of 17p and most cases with dmins have c-myc gene amplification. Meningiomas have losses or deletions of chromosome 22. Identification of these specific cytogenetic abnormalities in human brain tumors has provided the framework for identifying genes which are amplified in them and has identified chromosomal regions likely to contain tumor suppressor genes, the loss or inactivation of which is important in the development of these tumors.

Citing Articles

Epidemiology of primary brain tumor among adolescents and adults in Palestine: a retrospective study from 2018 to 2023.

Abuawad M, Daqour A, Alkaiyat A, Rjoub A, Zahra W, Issa N BMC Neurol. 2024; 24(1):168.

PMID: 38783212 PMC: 11112926. DOI: 10.1186/s12883-024-03677-1.


Extrachromosomal DNA in cancer.

Yan X, Mischel P, Chang H Nat Rev Cancer. 2024; 24(4):261-273.

PMID: 38409389 DOI: 10.1038/s41568-024-00669-8.


Aneuploidy and complex genomic rearrangements in cancer evolution.

Baker T, Waise S, Tarabichi M, Van Loo P Nat Cancer. 2024; 5(2):228-239.

PMID: 38286829 PMC: 7616040. DOI: 10.1038/s43018-023-00711-y.


Gene regulation on extrachromosomal DNA.

Hung K, Mischel P, Chang H Nat Struct Mol Biol. 2022; 29(8):736-744.

PMID: 35948767 PMC: 10246724. DOI: 10.1038/s41594-022-00806-7.


ADAR3 activates NF-κB signaling and promotes glioblastoma cell resistance to temozolomide.

Raghava Kurup R, Oakes E, Vadlamani P, Nwosu O, Danthi P, Hundley H Sci Rep. 2022; 12(1):13362.

PMID: 35922651 PMC: 9349284. DOI: 10.1038/s41598-022-17559-4.